COVID-19 — assessment & treatment (SARS-CoV-2; viral pneumonia)
covid-19-management · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Acute SARS-CoV-2 infection ranging from mild upper-respiratory illness to viral pneumonia with hypoxaemic respiratory failure. Management is severity-based: antivirals for high-risk outpatients within the early window; dexamethasone (+/- an immunomodulator) only for those needing supplemental oxygen; supportive oxygen/NIV/escalation for hypoxaemia.
Red flags
- SpO2 <=92% on air or exertional desaturation
- Rising respiratory rate / work of breathing / silent hypoxia
- Haemodynamic instability
- Suspected PE (pleuritic pain, disproportionate hypoxaemia, raised D-dimer)
- Immunosuppressed or incompletely vaccinated with progressing disease
- Secondary bacterial/fungal infection
Assessment
Differential diagnosis
- Influenza and other viral pneumonias
- Bacterial community-acquired pneumonia / co-infection
- Pulmonary embolism (raised risk in COVID)
- Heart failure / fluid overload
- COPD or asthma exacerbation
- Pneumocystis jirovecii pneumonia (immunosuppressed)
Investigations
- SARS-CoV-2 PCR or rapid antigen test
- Pulse oximetry (+/- exertional desaturation); ABG if hypoxaemic
- CXR +/- CT; CTPA if PE suspected (consider given prothrombotic state)
- FBC, U&E, LFTs, CRP; consider ferritin, D-dimer, LDH
- Bacterial cultures / sputum if secondary infection suspected
- ECG (QTc baseline), especially before QT-affecting drugs
- Risk-stratify for progression: age, immunosuppression, comorbidity, vaccination status
Management
- Assess severity and oxygenation; give controlled oxygen targeting SpO2 ~92-96% (88-92% if chronic hypercapnia risk)
- Mild, high-risk outpatient within ~5 days of onset: offer an antiviral (nirmatrelvir-ritonavir preferred where no major interactions; alternatives remdesivir or molnupiravir) to reduce progression
- Hospitalised NEEDING supplemental oxygen: start dexamethasone 6 mg once daily for up to 10 days
- Consider adding an immunomodulator (tocilizumab OR baricitinib) for rapidly escalating oxygen needs / systemic inflammation, in addition to steroid — do not combine the two immunomodulators
- Consider remdesivir in hospitalised patients on low-flow oxygen (less benefit once ventilated)
- Escalate respiratory support: high-flow nasal oxygen, awake proning, NIV/CPAP, then invasive ventilation and ARDS management as needed
- VTE prophylaxis for all admitted patients (higher thrombotic risk); treat confirmed PE
- Treat bacterial co-infection only if evidence; do NOT give steroids to patients not needing oxygen
Drugs & doses
Nirmatrelvir 300 mg + ritonavir 100 mg PO twice daily for 5 days — early high-risk outpatients; CHECK drug interactions and renal dose [verify interactions]
Remdesivir 200 mg IV day 1 then 100 mg IV once daily (3 days outpatient / up to 5 days inpatient on oxygen) [verify local protocol]
Molnupiravir 800 mg PO twice daily for 5 days — alternative where preferred agents unsuitable (not in pregnancy) [verify eligibility]
Dexamethasone 6 mg PO/IV once daily for up to 10 days — ONLY if requiring supplemental oxygen
Tocilizumab 8 mg/kg IV (single dose, max ~800 mg; may repeat) — add to steroid for severe/progressing disease [verify local protocol]
Baricitinib 4 mg PO once daily for up to 14 days — alternative immunomodulator to tocilizumab (renal adjustment) [verify local protocol]
Thromboprophylaxis e.g. enoxaparin 40 mg SC once daily (treatment dose if confirmed VTE) [verify weight/renal dose]
Disposition
Discharge mild cases with safety-netting; high-risk outpatients consider early antiviral. Admit for hypoxaemia/oxygen need or clinical concern. Escalate to HDU/ICU for high-flow oxygen, NIV, or ventilation.
Complications & pitfalls
- Hypoxaemic respiratory failure / ARDS
- Venous and arterial thromboembolism
- Secondary bacterial and fungal (incl. aspergillosis) infection
- Myocardial injury, arrhythmia
- Acute kidney injury
- Steroid/immunomodulator-related: hyperglycaemia, infection risk
- Post-COVID / long-COVID sequelae
Exam pearls
- Dexamethasone benefits only patients needing supplemental oxygen and may HARM those who do not — withhold if no oxygen requirement (RECOVERY trial; NICE NG191).
- Give early antivirals to high-risk outpatients within the first ~5 days of symptoms; nirmatrelvir-ritonavir has many drug interactions via ritonavir — check carefully.
- Tocilizumab or baricitinib (one, not both) added to steroid reduces mortality in severe/progressing disease (RECOVERY; NICE).
- COVID is prothrombotic — ensure VTE prophylaxis and keep a low threshold to investigate for PE.
- Evidence and recommendations evolve with variants and vaccination status — verify against current NICE/IDSA/WHO guidance.
- Awake proning and HFNO can delay/avoid intubation in cooperative hypoxaemic patients.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.